TrialReach, a London, U.K.-based provider of clinical trial information, raised $13.5M in Series B financing.
The round was led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments.
The company intends to use the funds to support the growth of its clinical trial platform and expansion into the U.S.
Founded in 2010 and led by Pablo Graiver, CEO, TrialReach aims to connect patients with clinical trials via a platform designed to aggregate and structure all clinical trial listings worldwide. In addition, the solution gives trial sponsors the opportunity to describe trials and patient criteria in a non-clinical manner that’s easier for patients to understand.
The company is working with health organizations, including WHO, pharmaceutical companies and partners with major health portals including Healthline, Everyday Health and CenterWatch as well as some patient networks such as WEGO Health and CureClick.